Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1) [Etude Phase I/II d'immunotherapie Par proteine recWT1-A10+AS01B apres Greffe allogenique de Cellules Souches]

Trial Profile

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1) [Etude Phase I/II d'immunotherapie Par proteine recWT1-A10+AS01B apres Greffe allogenique de Cellules Souches]

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Acute myeloid leukaemia vaccine (Primary) ; AS01B
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms ALLO-WT1
  • Most Recent Events

    • 19 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2013 New source identified and integrated: European Clinical Trials Database record.
    • 10 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top